Stocks
Genelux CorporationGNLX
NASDAQHealthcareBiotechnology$2.00
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for solid tumors. Its lead candidate, olvi-vec, is being evaluated in late-stage trials for ovarian cancer and other indications. Investors track the stock for its potential in the immuno-oncology space, though it remains highly speculative with no approved products.
52W Range: $1.90-$8.54
Congressional Interest in Genelux Corporation (GNLX)
No congressional trades have been disclosed for Genelux Corporation (GNLX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading GNLX?
No congressional trades found for this stock.